MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: IPSEN Group
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019 - Presentations showcase insights in advanced renal cell carcinoma, gastroenteropancreatic neuroendocrine tumors and acromegaly - ISPOR.org / IPSEN.com
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019

 

NewswireToday - /newswire/ - Paris, Ile-de-France, France, 2019/10/31 - Presentations showcase insights in advanced renal cell carcinoma, gastroenteropancreatic neuroendocrine tumors and acromegaly - ISPOR.org / IPSEN.com. Euronext: IPN; ADR: IPSEY

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Ipsen today announced that results from a network meta-analysis (NMA) in advanced renal cell carcinoma (aRCC), and a UK-focused budget impact study assessing long-acting somatostatin analogues (LA-SSAs) for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP NET) will be presented at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2019 Annual Conference. ISPOR (ispor.org) takes place in Copenhagen, Denmark from 2-6 November 2019.

Key studies to be presented at ISPOR Europe 2019:

An assessment of the budget impact of LA-SSAs in the treatment of acromegaly and GEP NET, considering attributes related to the drug delivery of LA-SSAs in the UK.
An NMA analyzing cabozantinib versus standard-of-care comparators in progression free survival (PFS) and overall survival (OS) in the first-line treatment of advanced renal cell carcinoma.

“We’re excited to be sharing two interesting sets of results namely a comparison of first-line therapies and budget impact of a treatment approach for acromegaly and gastroenteropancreatic neuroendocrine tumors,” said Ulf Staginnus, Senior Vice President, Head Global Market Access and Pricing, Ipsen. “With more than 5,000 global healthcare leaders, seeking robust health solutions and new insights, ISPOR Europe 2019 is the perfect stage to share these results.”

The delivery attributes of both LA-SSAs were considered in the UK-focused study assessing the budget impact of the LA-SSAs, lanreotide versus octreotide in the treatment of acromegaly and GEP-NET. Model inputs (including drug acquisition and administration costs) were based on publicly available sources. The analysis compared the current and hypothetical market share scenarios from three perspectives in the UK: the National Health Service (NHS), a regional clinical commissioning group (CCG), and a local institution (hospital). Results suggested that increasing the use of lanreotide to a hypothetical 80% market share for lanreotide in the UK would reduce overall LA-SSAs patient treatment expenses by £2.9 million annually in the UK (a reduction of 3.6% from the current budget estimate of £80.6 million).

In the area of treatment provision in aRCC, Ipsen (ipsen.com) used an NMA to respond to the challenge presented to healthcare professionals by the introduction of targeted therapies in the last year with no way to objectively compare them. While randomized trials are the gold standard for comparative effectiveness research, they are not always available for clinically and economically important treatment comparisons. In this case, the NMA may offer some helpful insights as it suggests that cabozantinib significantly increases progression free survival (PFS) in intermediate and poor-risk patients when compared with standards-of-care and concludes that cabozantinib may be considered as an efficient treatment option in first-line aRCC.

“Modern quantitative data reviews of available agents offer additional insights into existing healthcare,” said Bartek Bednarz, Senior Vice-President, Global Product and Portfolio Strategy, Ipsen. “The network meta-analysis (NMA) for cabozantinib and budget impact model for somatostatin analogues shared at ISPOR Europe 2019 are just part of Ipsen’s ongoing commitment to demonstrating benefit for payers and improving options for patients with high unmet needs.”

About IPSEN PRODUCTS

This press release mentions investigational uses of Ipsen products. Product indications and approvals for use vary by jurisdiction; please see SmPC/PI for full indications and safety information, including Boxed Warnings.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: IPSEN Group

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Christian Marcoux - IPSEN.com 
+33(0)1 58 33 67 94 christian.marcoux[.]ipsen.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any IPSEN Group securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From IPSEN Group / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)